Oh DY - Search Results

1

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Yao JC, et al. Among authors: oh dy. Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17. Lancet. 2016. PMID: 26703889 Free PMC article. Clinical Trial.

2

The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.

Sun JM, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Lee JS, Kim YW, Heo DS, Bang YJ. Sun JM, et al. Among authors: oh dy. Lung Cancer. 2010 Jun;68(3):427-32. doi: 10.1016/j.lungcan.2009.07.013. Epub 2009 Aug 11. Lung Cancer. 2010. PMID: 19674811

3

Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy.

Kim SJ, Kim JW, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Seog Heo D, Bang YJ. Kim SJ, et al. Among authors: oh dy. BMC Cancer. 2010 Aug 23;10:448. doi: 10.1186/1471-2407-10-448. BMC Cancer. 2010. PMID: 20731845 Free PMC article.

4

Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung).

Kim SJ, Kim JW, Oh DY, Han SW, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ. Kim SJ, et al. Among authors: oh dy. Am J Clin Oncol. 2012 Dec;35(6):549-56. doi: 10.1097/COC.0b013e31821dee0f. Am J Clin Oncol. 2012. PMID: 21659833

5

Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.

Oh DY, Kim TW, Park YS, Shin SJ, Shin SH, Song EK, Lee HJ, Lee KW, Bang YJ. Oh DY, et al. Cancer. 2012 Dec 15;118(24):6162-70. doi: 10.1002/cncr.27675. Epub 2012 Jun 26. Cancer. 2012. PMID: 22736481 Free article. Clinical Trial.

6

Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.

Lim KH, Han SW, Oh DY, Im SA, Kim TY, Bang YJ. Lim KH, et al. Among authors: oh dy. Oncology. 2012;83(2):57-66. doi: 10.1159/000338795. Epub 2012 Jun 29. Oncology. 2012. PMID: 22760079 Clinical Trial.

7

Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases.

Hur S, Chung JW, Kim HC, Oh DY, Lee SH, Bang YJ, Kim WH. Hur S, et al. Among authors: oh dy. J Vasc Interv Radiol. 2013 Jul;24(7):947-56; quiz 957. doi: 10.1016/j.jvir.2013.02.030. Epub 2013 Apr 19. J Vasc Interv Radiol. 2013. PMID: 23602421

8

The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy.

Choi Y, Kim TY, Oh DY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ. Choi Y, et al. Among authors: oh dy. Cancer Res Treat. 2016 Jan;48(1):171-9. doi: 10.4143/crt.2014.292. Epub 2015 Mar 13. Cancer Res Treat. 2016. PMID: 25779362 Free PMC article.

9

TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials.

Lee DW, Jang MJ, Lee KH, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH, Kim TY, Han SW, Oh DY, Im SA, Kim TY. Lee DW, et al. Among authors: oh dy. Br J Cancer. 2016 Nov 8;115(10):1201-1205. doi: 10.1038/bjc.2016.322. Epub 2016 Oct 13. Br J Cancer. 2016. PMID: 27736843 Free PMC article.

10

Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary.

Singh S, Carnaghi C, Buzzoni R, Pommier RF, Raderer M, Tomasek J, Lahner H, Valle JW, Voi M, Bubuteishvili-Pacaud L, Lincy J, Wolin E, Okita N, Libutti SK, Oh DY, Kulke M, Strosberg J, Yao JC, Pavel ME, Fazio N; RAD001 in Advanced Neuroendocrine Tumors, Fourth Trial (RADIANT-4) Study Group. Singh S, et al. Among authors: oh dy. Neuroendocrinology. 2018;106(3):211-220. doi: 10.1159/000477585. Epub 2017 May 24. Neuroendocrinology. 2018. PMID: 28554173 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

784 results

Search Page

Filters